Plant Nanovesicles Integrate Bioactivity and Transdermal Finasteride Delivery for Androgenetic Alopecia.
Abstract
Androgenetic alopecia (AGA) is a progressive hair loss disorder with limited effective therapeutic options. Although finasteride (FIN) remains a first-line treatment, its oral administration is frequently associated with systemic side effects. To overcome this limitation, we developed biomimetic Platycladi cacumen-derived nanovesicles (PcNs)─a traditional medicinal herb known for its hair-growth-promoting properties─as multifunctional carriers for transdermal FIN delivery. PcNs significantly enhanced skin permeation and local drug retention, promoting drug accumulation within the epidermal and dermal layers, while concurrently reducing oxidative stress. In a testosterone-induced AGA mouse model, topical application of FIN-loaded PcNs (FIN-PcNs) effectively reversed hair follicle miniaturization and robustly stimulated hair regeneration. Compared to minoxidil, FIN-PcNs exhibited superior therapeutic efficacy in promoting hair regrowth. Mechanistically, PcNs alleviated hair loss by scavenging reactive oxygen species, modulating inflammatory signaling pathways, and upregulating key genes associated with hair follicle regeneration. Collectively, this study presents a plant-derived nanovesicle-based transdermal platform that integrates intrinsic bioactivity with local drug delivery, offering a safe and effective strategy for AGA treatment and underscoring the broader potential of plant-derived nanocarriers in precision dermatology.
Resumo Rápido
A plant-derived nanovesicle-based transdermal platform that integrates intrinsic bioactivity with local drug delivery is presented, offering a safe and effective strategy for AGA treatment and underscoring the broader potential of plant-derived nanocarriers in precision dermatology.
Used In Evidence Reviews
Similar Papers
Annual review of nutrition · 2004
Secular trends in dietary intake in the United States.
Journal of the American Academy of Dermatology · 1998
Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.
Endocrine · 2017
Androgenetic alopecia: a review.
Journal of the American Academy of Dermatology · 2002
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Journal of the American Academy of Dermatology · 2017
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
Current problems in dermatology · 2015